Nuedexta (dextromethorphan HBr and quinidine sulfate) vs Olpruva (sodium phenylbutyrate)
Nuedexta (dextromethorphan HBr and quinidine sulfate) vs Olpruva (sodium phenylbutyrate)
Nuedexta and Olpruva are two very different medications used for distinct medical conditions. Nuedexta combines dextromethorphan and quinidine and is primarily used to treat pseudobulbar affect (PBA), a condition characterized by sudden and uncontrollable laughing or crying, often seen in patients with certain neurological conditions or brain injuries. On the other hand, Olpruva (sodium phenylbutyrate) is used for the treatment of urea cycle disorders, which are genetic disorders that result in a deficiency of one of the enzymes in the urea cycle, leading to an accumulation of ammonia in the blood. For someone deciding which medicine is right for them, it is crucial to consider the medical condition being treated: Nuedexta is appropriate for PBA, while Olpruva is for managing urea cycle disorders. It is essential to consult a healthcare professional to determine the appropriate treatment based on the individual's specific medical needs and condition.
Difference between Nuedexta and Olpruva
| Metric | Nuedexta (dextromethorphan HBr and quinidine sulfate) | Olpruva (sodium phenylbutyrate) |
|---|---|---|
| Generic name | Dextromethorphan hydrobromide and quinidine sulfate | Sodium phenylbutyrate |
| Indications | Treatment of pseudobulbar affect (PBA) | Urea cycle disorders |
| Mechanism of action | Dextromethorphan acts on the central nervous system to modulate the excitatory neurotransmitter glutamate, while quinidine inhibits cytochrome P450 2D6 to increase the bioavailability of dextromethorphan | Converts to phenylacetate in the body, which then conjugates with glutamine to form phenylacetylglutamine, thereby reducing ammonia levels in the blood |
| Brand names | Nuedexta | Buphenyl, Ammonaps, Pheburane |
| Administrative route | Oral | Oral |
| Side effects | Dizziness, nausea, cough, vomiting, peripheral edema, diarrhea, urinary tract infections, influenza, increased gamma-glutamyltransferase, and flatulence | Body odor, taste aversion, nausea, headache, fatigue, rash, and anorexia |
| Contraindications | Patients taking monoamine oxidase inhibitors (MAOIs) or with a history of heart disease, prolonged QT interval, or heart rhythm disorders | Patients with hypersensitivity to sodium phenylbutyrate or its analogs |
| Drug class | Central nervous system agent | Urea cycle disorder agent |
| Manufacturer | Avanir Pharmaceuticals | Horizon Pharma (Buphenyl), Swedish Orphan Biovitrum (Ammonaps, Pheburane) |
Efficacy
Nuedexta and ALS
Nuedexta, a combination of dextromethorphan HBr and quinidine sulfate, is primarily approved for the treatment of pseudobulbar affect (PBA), a condition characterized by uncontrollable episodes of crying and/or laughing that is disproportionate or incongruent to the patient's emotional state. While PBA can occur in patients with various neurological conditions, including amyotrophic lateral sclerosis (ALS), Nuedexta is not specifically approved for the treatment of ALS itself. However, the efficacy of Nuedexta in managing PBA symptoms in ALS patients has been recognized, providing relief for those experiencing these emotional disturbances.
Studies investigating the direct impact of Nuedexta on the progression of ALS or its primary symptoms have been limited. The primary focus of Nuedexta's use in ALS patients remains on the management of PBA. As such, while it may improve quality of life for ALS patients by addressing PBA, there is insufficient evidence to suggest that Nuedexta has a significant effect on the underlying ALS disease process or its progression.
Olpruva and ALS
Olpruva, known generically as sodium phenylbutyrate, is a medication that has been explored for its potential off-label use in ALS. Sodium phenylbutyrate is traditionally used for the treatment of urea cycle disorders, which are genetic disorders that result in an inability to remove ammonia from the bloodstream. Its efficacy in ALS is thought to be related to its potential to modulate cellular stress responses, which might be beneficial in neurodegenerative diseases like ALS.
Research into the use of sodium phenylbutyrate for ALS has yielded mixed results. Some studies have suggested that it may have a neuroprotective effect and could potentially slow the progression of ALS or improve survival. However, these findings are not definitive, and more research is needed to fully understand the potential benefits of Olpruva in the treatment of ALS. As of the current knowledge cutoff, Olpruva is not approved by regulatory agencies specifically for the treatment of ALS, and its use remains off-label with efficacy data still being collected and analyzed.
Regulatory Agency Approvals
Nuedexta
-
Food and Drug Administration (FDA), USA
Olpruva
-
Food and Drug Administration (FDA), USA
Access Nuedexta or Olpruva today
If Nuedexta or Olpruva are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us